pharmaphorum October 15, 2025
Johnson & Johnson has said it wants to spin off its orthopaedics division as part of an effort to redirect its business towards higher-growth areas.
The announcement – made as the company raised its sales growth guidance for 2026 to 5% – is the second major divestment for J&J in recent years, coming after the separation of its consumer health business into the $15 billion standalone company Kenvue in 2023.
The orthopaedic business, which makes products like replacement joints, trauma products, and surgical instruments, will operate under the DePuy Synthes banner and be led by Namal Nawana, an industry veteran whose CV includes a role as former chief executive of medtech company Smith & Nephew.
It has been starting to...
Today's Sponsors
Today's Sponsor